Precigen reported second quarter 2026 financial results, achieving net income of $20.1 million ($0.06 per basic share) compared to a net loss in the prior year period. Total revenues reached $55.0 million, driven by PAPZIMEOS product revenue of $53.1 million, which more than doubled from the previous quarter. The company reported cash, cash equivalents, and investments totaling $38.7 million as of June 30, 2026, projecting a path to cash flow break-even by year-end 2026. Additionally, the FDA granted PAPZIMEOS seven-year market exclusivity, and patient hub enrollment exceeded 500 patients. Precigen is a commercial-stage biopharmaceutical company specializing in precision medicines for difficult-to-treat diseases.

At its annual meeting on June 18, 2026, Precigen, Inc. stockholders approved an amendment to the 2023 Omnibus Incentive Plan to increase the number of common shares available for issuance by 7 million. Additionally, shareholders elected nine directors for one-year terms, ratified Deloitte & Touche LLP as the independent registered public accounting firm for the 2026 fiscal year, and approved a non-binding advisory resolution regarding executive compensation. Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies.